New pill aims to keep depression away longer

NCT ID NCT07196501

Recruiting now Disease control Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This Phase 3 study tests whether adding NBI-1065845 to standard antidepressants can delay the return of depressive symptoms in adults with major depression. About 550 people who have not fully responded to current antidepressants will take either the study drug or a placebo pill. The main goal is to see how long it takes for depression symptoms to come back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NBI-1065845 (oral tablet)
What this could lead to: If it works, this could provide a new add-on option to help people with major depression stay well longer and delay relapse.
What could go wrong: This is a Phase 3 trial, but it's still experimental. The drug may not work better than placebo, and side effects are possible. Results may not apply to everyone with depression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dysthymic disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Neurocrine Clinical Site
RECRUITING

Oceanside, California, 92056, United States
Neurocrine Clinical Site
RECRUITING

Orange, California, 92868, United States
Neurocrine Clinical Site
RECRUITING

San Jose, California, 95124, United States
Neurocrine Clinical Site
RECRUITING

New Haven, Connecticut, 06520, United States
Neurocrine Clinical Site
RECRUITING

Miami Gardens, Florida, 33014, United States
Neurocrine Clinical Site
RECRUITING

Orlando, Florida, 32803, United States
Neurocrine Clinical Site
RECRUITING

Palm Bay, Florida, 32905, United States
Neurocrine Clinical Site
RECRUITING

Tampa, Florida, 33629, United States
Neurocrine Clinical Site
RECRUITING

Iowa City, Iowa, 52242, United States
Neurocrine Clinical Site
RECRUITING

Marrero, Louisiana, 70072, United States
Neurocrine Clinical Site
RECRUITING

O'Fallon, Missouri, 63368, United States
Neurocrine Clinical Site
RECRUITING

Albuquerque, New Mexico, 87109, United States
Neurocrine Clinical Site
RECRUITING

Glen Oaks, New York, 11004, United States
Neurocrine Clinical Site
RECRUITING

Charlotte, North Carolina, 28211, United States
Neurocrine Clinical Site
RECRUITING

Edmond, Oklahoma, 73013, United States
Neurocrine Clinical Site
RECRUITING

Oklahoma City, Oklahoma, 73112, United States
Neurocrine Clinical Site
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Neurocrine Clinical Site
ACTIVE_NOT_RECRUITING

Austin, Texas, 78712, United States
Neurocrine Clinical Site
RECRUITING

Bellaire, Texas, 77401, United States
Neurocrine Clinical Site
TERMINATED

Friendswood, Texas, 77546, United States
Neurocrine Clinical Site
RECRUITING

Stafford, Texas, 77477, United States
Neurocrine Clinical Site
RECRUITING

Wichita Falls, Texas, 76309, United States
Neurocrine Clinical Site
RECRUITING

Draper, Utah, 84020, United States
Neurocrine Clinical Site
RECRUITING

Roanoke, Virginia, 24018, United States
Neurocrine Clinical Site
RECRUITING

Carlton, Victoria, 3053, Australia
Neurocrine Clinical Site
RECRUITING

Melbourne, Victoria, 3004, Australia
Neurocrine Clinical Site
RECRUITING

Parkville, Victoria, 3050, Australia
Neurocrine Clinical Site
RECRUITING

Sofia, 1303, Bulgaria
Neurocrine Clinical Site
RECRUITING

Sofia, 1408, Bulgaria
Neurocrine Clinical Site
RECRUITING

Sofia, 1510, Bulgaria
Neurocrine Clinical Site
RECRUITING

Sofia, 1680, Bulgaria
Neurocrine Clinical Site
RECRUITING

Calgary, Alberta, T2N 2T9, Canada
Neurocrine Clinical Site
RECRUITING

North Vancouver, British Columbia, V7P 2T4, Canada
Neurocrine Clinical Site
RECRUITING

Kingston, Ontario, K7L 4X3, Canada
Neurocrine Clinical Site
RECRUITING

Sherbrooke, Quebec, J1L 0H8, Canada
Neurocrine Clinical Site
RECRUITING

Toronto, M5H 1A1, Canada
Neurocrine Clinical Site
RECRUITING

Tallinn, 10138, Estonia
Neurocrine Clinical Site
RECRUITING

Tallinn, 11315, Estonia
Neurocrine Clinical Site
RECRUITING

Tartu, 50417, Estonia
Neurocrine Clinical Site
WITHDRAWN

Milan, 20127, Italy
Neurocrine Clinical Site
RECRUITING

Roma, 168, Italy
Neurocrine Clinical Site
RECRUITING

Rome, 168, Italy
Neurocrine Clinical Site
RECRUITING

Torino, 10126, Italy
Neurocrine Clinical Site
RECRUITING

Bialystok, 15-879, Poland
Neurocrine Clinical Site
RECRUITING

Bydgoszcz, 85-794, Poland
Neurocrine Clinical Site
RECRUITING

Gdansk, 80-283, Poland
Neurocrine Clinical Site
RECRUITING

Belgrade, 11000, Serbia
Neurocrine Clinical Site
RECRUITING

Kovin, 26220, Serbia
Neurocrine Clinical Site
RECRUITING

Kragujevac, 34000, Serbia
Neurocrine Clinical Site
RECRUITING

Ansan-si, Gyeonggi-do, 15355, South Korea
Neurocrine Clinical Site
RECRUITING

Seoul, 02841, South Korea
Neurocrine Clinical Site
RECRUITING

Seoul, 06351, South Korea
Neurocrine Clinical Site
RECRUITING

Seoul, 3181, South Korea
Neurocrine Clinical Site
RECRUITING

Alcorcón, Madrid, 28922, Spain
Neurocrine Clinical Site
RECRUITING

Barcelona, 08025, Spain
Neurocrine Clinical Site
RECRUITING

Barcelona, 08035, Spain
Neurocrine Clinical Site
RECRUITING

Keelung, 204, Taiwan
Neurocrine Clinical Site
RECRUITING

Taipei, 10449, Taiwan
Neurocrine Clinical Site
RECRUITING

Taipei, 110, Taiwan
Neurocrine Clinical Site
RECRUITING

Taipei, 11217, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.